Pharma Capital

OncoSil Medical wins key approval

OncoSil is focused on treatments for pancreatic and liver cancer.
6862528879_c9e63bfaa0_o_opt_opt-(1).jpg
OncoSil's shares have gained recently

OncoSil Medical (ASX:OSL) has received approval from the Institutional Review Board (IRB) of the MD Anderson Cancer Center at the University of Texas for its global clinical study program in pancreatic cancer.

The approval is the final step for US hospitals to agree to participate in a clinical study and recruit and treat patients under the agreed study protocols.

MD Anderson will now finalise site initiation and complete final training before first patient recruitment which is anticipated to occur in May.

Daniel Kenny, CEO, commented:

"We are pleased to make continued progress with our clinic operations in the US, and are encouraged by the engagement of our study center partners in working toward the treatment of patients as part of this important global study in pancreatic cancer."


What is OncoSil™

OncoSil's lead product, OncoSil™, is a targeted radioactive isotope (Phosphorous-32), implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound.

Treatment with OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation.


Share price re-rating

OncoSil has recently started ticking off milestones, and the market has re-rated the stock on the back of these.

Shares in the company have hit $0.13 this week, which is 63% higher than one-month ago.

View full OSL profile

OncoSil Medical Ltd Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.